Humulin M3 Kwikpen (Mixture 3) (Insulin Human (Rdna))

Humulin M3 Kwikpen is indicated for the management of blood glucose in patients with diabetes who require a combination of rapid and intermediate insulin action.

• Initiation of basal‑bolus therapy in type 1 diabetes mellitus.
• Supplemental insulin for type 2 diabetes mellitus when oral agents are insufficient.
• Adjustment of insulin regimen during periods of variable carbohydrate intake.
• Use in adults and children (≥2 years) who can safely handle a pre‑filled pen.
• Replacement of separate short‑acting and intermediate‑acting insulin injections with a single device.

• Insulin human binds to the insulin receptor on cell membranes, activating the intrinsic tyrosine kinase activity of the receptor. This triggers downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the plasma membrane and enhancing glucose uptake in muscle and adipose tissue. It also suppresses hepatic gluconeogenesis, leading to reduced circulating glucose concentrations. The mixed formulation provides an early peak from the rapid component and a prolonged effect from the intermediate component, allowing fewer daily injections.

Like all insulin products, Humulin M3 Kwikpen may be associated with adverse reactions, which can be categorized by frequency and severity.

Common

• Mild hypoglycemia (symptoms such as shakiness, sweating, or hunger)
• Injection site reactions (redness, swelling, or itching)
• Lipodystrophy (localized thickening or loss of subcutaneous fat)
• Transient weight gain

Serious

• Severe hypoglycemia with loss of consciousness or seizures
• Allergic reactions including urticaria, angioedema, or anaphylaxis
• Persistent hyperglycemia due to insulin resistance or dosing error

Healthcare providers should consider several precautions when prescribing Humulin M3 Kwikpen to ensure safe and effective use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Avoid use in patients with known hypersensitivity to human insulin or excipients.
• Adjust dose during periods of illness, fasting, or increased physical activity.
• Monitor blood glucose regularly, especially when initiating therapy or changing dose.
• Use caution in pregnancy; benefits must be weighed against potential risks.

Insulin therapy can interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid

• Concurrent use of high‑dose sulfonylureas or meglitinides that may cause profound hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms.

Use with caution

• Corticosteroids, thiazide diuretics, and growth hormone, which can raise blood glucose.
• Oral contraceptives and hormone replacement therapy, which may alter insulin requirements.
• Alcohol, especially in excess, which can precipitate delayed hypoglycemia.
• ACE inhibitors and ARBs, which may potentiate insulin’s glucose‑lowering effect.